Crossmark Global Holdings Inc. Sells 21,681 Shares of Cencora, Inc. (NYSE:COR)

Crossmark Global Holdings Inc. cut its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 54.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,781 shares of the company's stock after selling 21,681 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Cencora were worth $4,945,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in COR. Hoey Investments Inc. acquired a new position in Cencora in the first quarter worth approximately $28,000. Banque Transatlantique SA acquired a new position in shares of Cencora in the 4th quarter valued at $29,000. SBI Securities Co. Ltd. purchased a new position in Cencora in the 4th quarter worth about $30,000. Vermillion Wealth Management Inc. acquired a new position in Cencora in the 4th quarter worth approximately $38,000. Finally, OFI Invest Asset Management purchased a new position in Cencora during the 4th quarter worth approximately $41,000. Institutional investors own 97.52% of the company's stock.

Cencora Stock Down 0.8%

COR stock traded down $2.25 during mid-day trading on Friday, reaching $295.07. The company had a trading volume of 963,863 shares, compared to its average volume of 1,507,719. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52. The stock has a 50 day simple moving average of $291.85 and a two-hundred day simple moving average of $269.23. The company has a market capitalization of $57.19 billion, a price-to-earnings ratio of 34.23, a PEG ratio of 1.49 and a beta of 0.57. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter last year, the firm posted $3.80 EPS. The company's quarterly revenue was up 10.3% on a year-over-year basis. As a group, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Analyst Ratings Changes

Several research firms have weighed in on COR. Citigroup lifted their price objective on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Bank of America lifted their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Robert W. Baird lifted their price objective on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research note on Tuesday, April 15th. Finally, Jefferies Financial Group lifted their target price on shares of Cencora from $275.00 to $300.00 and gave the company a "hold" rating in a research note on Monday, June 30th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Cencora has an average rating of "Moderate Buy" and an average target price of $306.33.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the sale, the chairman owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer directly owned 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 34,127 shares of company stock valued at $9,812,296. Insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.